Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia

Completed · Phase 2

Conditions studied: Myelogenous Leukemia, Acute

In brief

The purpose of this study is to determine how effective, and to what extent, Iressa is in the treatment of acute myelogenous leukemia.

Key facts

Study ID

NCT00130702

Run by

Dana-Farber Cancer Institute

People needed

18

Starts

2005-08-01

Expected to finish

2007-11-01

Last updated by the study team

2014-05-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must have pathologically documented acute myelogenous leukemia and either not be a candidate for myelosuppressive chemotherapy due to age or comorbid disease; or have relapsed acute myelogenous leukemia or be refractory to standard therapy and not likely to require cytoreductive therapy within 30 days.
• ECOG performance status 0, 1 or 2
• Age > 18 years
• Adequate kidney and hepatic function
• Greater than 4 weeks from any chemotherapy, radiotherapy, immunotherapy, or systemic steroid therapy with the exception of hydroxyurea.
• Greater than 2 months following bone marrow or peripheral blood stem cell transplantation or donor lymphocyte infusion.

You may not qualify if…

• Uncontrolled active infection
• Urgent need for cytoreductive chemotherapy, surgery, or radiotherapy
• Current chemotherapy or chemotherapy within the last 4 weeks.
• Pregnancy or nursing mothers
• Infection with HIV

Where it is running

• Dana-Farber Cancer Institute — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.